Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

Udeni B R Balasuriya, Hans W. Heidner, Nancy L. Davis, Heike M. Wagner, Pam Hullinger, Jodi F. Hedges, Jacqueline C. Williams, Robert E. Johnston, William D Wilson, Irwin Liu, Nigel J Maclachlan

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (GL and M) of equine arteritis virus (EAV), both individually and in heterodimer form (GL/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the GL and M proteins in heterodimer form developed neutralizing antibodies to EAV, shed little or no virus, and developed only mild or inapparent signs of equine viral arteritis (EVA) after challenge with EAV KY84. In contrast, unvaccinated horses and those immunized with replicons expressing individual EAV envelope proteins (M or GL) shed virus for 6-10 days in their nasal secretions and developed severe signs of EVA after challenge. These data confirm that replicons that co-express the GL and M envelope proteins effectively, induce EAV neutralizing antibodies and protective immunity in horses.

Original languageEnglish (US)
Pages (from-to)1609-1617
Number of pages9
JournalVaccine
Volume20
Issue number11-12
DOIs
StatePublished - Feb 22 2002

Fingerprint

Equine Arteritis Virus
Equine arteritis virus
Alphavirus
replicon
Replicon
Horses
Viruses
horses
viruses
Proteins
proteins
arteritis
Arteritis
Neutralizing Antibodies
neutralizing antibodies
Venezuelan Equine Encephalitis Viruses
Venezuelan equine encephalitis virus
Viral Envelope Proteins
sheds
Nose

Keywords

  • EAV
  • Vaccination
  • VEE

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. / Balasuriya, Udeni B R; Heidner, Hans W.; Davis, Nancy L.; Wagner, Heike M.; Hullinger, Pam; Hedges, Jodi F.; Williams, Jacqueline C.; Johnston, Robert E.; Wilson, William D; Liu, Irwin; Maclachlan, Nigel J.

In: Vaccine, Vol. 20, No. 11-12, 22.02.2002, p. 1609-1617.

Research output: Contribution to journalArticle

Balasuriya, Udeni B R ; Heidner, Hans W. ; Davis, Nancy L. ; Wagner, Heike M. ; Hullinger, Pam ; Hedges, Jodi F. ; Williams, Jacqueline C. ; Johnston, Robert E. ; Wilson, William D ; Liu, Irwin ; Maclachlan, Nigel J. / Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. In: Vaccine. 2002 ; Vol. 20, No. 11-12. pp. 1609-1617.
@article{78d7caf15d724787ba3e9bc1d70a7c4d,
title = "Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses",
abstract = "Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (GL and M) of equine arteritis virus (EAV), both individually and in heterodimer form (GL/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the GL and M proteins in heterodimer form developed neutralizing antibodies to EAV, shed little or no virus, and developed only mild or inapparent signs of equine viral arteritis (EVA) after challenge with EAV KY84. In contrast, unvaccinated horses and those immunized with replicons expressing individual EAV envelope proteins (M or GL) shed virus for 6-10 days in their nasal secretions and developed severe signs of EVA after challenge. These data confirm that replicons that co-express the GL and M envelope proteins effectively, induce EAV neutralizing antibodies and protective immunity in horses.",
keywords = "EAV, Vaccination, VEE",
author = "Balasuriya, {Udeni B R} and Heidner, {Hans W.} and Davis, {Nancy L.} and Wagner, {Heike M.} and Pam Hullinger and Hedges, {Jodi F.} and Williams, {Jacqueline C.} and Johnston, {Robert E.} and Wilson, {William D} and Irwin Liu and Maclachlan, {Nigel J}",
year = "2002",
month = "2",
day = "22",
doi = "10.1016/S0264-410X(01)00485-6",
language = "English (US)",
volume = "20",
pages = "1609--1617",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11-12",

}

TY - JOUR

T1 - Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

AU - Balasuriya, Udeni B R

AU - Heidner, Hans W.

AU - Davis, Nancy L.

AU - Wagner, Heike M.

AU - Hullinger, Pam

AU - Hedges, Jodi F.

AU - Williams, Jacqueline C.

AU - Johnston, Robert E.

AU - Wilson, William D

AU - Liu, Irwin

AU - Maclachlan, Nigel J

PY - 2002/2/22

Y1 - 2002/2/22

N2 - Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (GL and M) of equine arteritis virus (EAV), both individually and in heterodimer form (GL/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the GL and M proteins in heterodimer form developed neutralizing antibodies to EAV, shed little or no virus, and developed only mild or inapparent signs of equine viral arteritis (EVA) after challenge with EAV KY84. In contrast, unvaccinated horses and those immunized with replicons expressing individual EAV envelope proteins (M or GL) shed virus for 6-10 days in their nasal secretions and developed severe signs of EVA after challenge. These data confirm that replicons that co-express the GL and M envelope proteins effectively, induce EAV neutralizing antibodies and protective immunity in horses.

AB - Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (GL and M) of equine arteritis virus (EAV), both individually and in heterodimer form (GL/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the GL and M proteins in heterodimer form developed neutralizing antibodies to EAV, shed little or no virus, and developed only mild or inapparent signs of equine viral arteritis (EVA) after challenge with EAV KY84. In contrast, unvaccinated horses and those immunized with replicons expressing individual EAV envelope proteins (M or GL) shed virus for 6-10 days in their nasal secretions and developed severe signs of EVA after challenge. These data confirm that replicons that co-express the GL and M envelope proteins effectively, induce EAV neutralizing antibodies and protective immunity in horses.

KW - EAV

KW - Vaccination

KW - VEE

UR - http://www.scopus.com/inward/record.url?scp=0037154783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037154783&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00485-6

DO - 10.1016/S0264-410X(01)00485-6

M3 - Article

C2 - 11858869

AN - SCOPUS:0037154783

VL - 20

SP - 1609

EP - 1617

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11-12

ER -